Actinium Pharmaceuticals Inc. (ATNM) 3.01 $ATNM
Actinium to Partner With Aplastic Anemia & MDS International Foundation Patient and Family Forums
Marketwired - Wed Apr 22, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is partnering with the Aplastic Anemia & MDS International Foundation, a leading non-profit health organization, to present educational forums to patients and their families on bone marrow transplant, MDS, aplastic anemia and PNH.
ATNM: 3.01 (-0.07)
Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 4.01 (-0.06), BIIB: 423.57 (+1.46), ARWR: 6.88 (+0.14), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), BMY: 66.60 (-0.21), CNCE: 14.83 (+0.26), CELG: 115.54 (+0.72), ATNM: 3.01 (-0.07), PFS: 18.65 (+0.06), NVIV: 13.76 (-0.19), GILD: 104.18 (-1.02), FWP: 31.77 (-0.66), GWPH: 113.04 (-0.05), IBM: 165.36 (+1.10), BAX: 70.38 (+0.33), AZN: 73.35 (+0.65), TEVA: 63.01 (-1.15)
Actinium Pharmaceuticals: An Undervalued Biotech Revolutionizing AML Treatment
Stock Doctor - Seeking Alpha - Thu Apr 16, 10:58AM CDT
Readers familiar with my biotechnology investing strategy know that I prefer small cap companies with underappreciated best-in-class drugs that address significant unmet clinical needs. I also like to pick stocks that have enough cash on hand in the...
ATNM: 3.01 (-0.07)
Actinium Doses the First Patient in the Fourth, Final Cohort of Its Actimab-A Trial
Marketwired - Wed Apr 15, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the first patient was successfully treated with Actimab-A drug candidate in the fourth and last cohort of the ongoing Phase 1/2 trial of Actimab-A. Actimab-A is being developed for newly diagnosed AML patients over the age of 60 ineligible for standard induction chemotherapy.
ATNM: 3.01 (-0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 11:44AM CDT
HK: 1.60 (-0.05), TOF: 4.12 (-0.03), VTAE: 14.04 (+0.02), NYMX: 1.32 (-0.08), VLTC: 15.14 (-1.04), CGNT: 1.63 (+0.08), RESN: 3.77 (-0.06), MHR: 2.34 (-0.07), GBSN: 4.98 (+1.44), NATH: 47.21 (+0.10), INUV: 2.32 (-0.05), ATNM: 3.01 (-0.07), SYPR: 1.50 (+0.04), TRGT: 2.30 (-0.02), QURE: 26.15 (-1.44), CYTX: 0.96 (-0.09), PRXI: 4.82 (+0.27), NPTN: 5.90 (unch), CBMG: 32.14 (+2.21), SA: 6.21 (-0.29)
Actinium Pharmaceuticals Opens Enrollment for the Fourth and Final Cohort in the Company's Ongoing Phase I/II Trial in Acute Myeloid Leukemia
Marketwired - Tue Mar 24, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the fourth cohort, who, in keeping with trial protocol, will be injected with two doses 4 to 7 days apart of the Company's investigational new drug Actimab-A at a higher activity level of 2.0 micronCi/kg per dose.
ATNM: 3.01 (-0.07)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 8:12AM CDT
AKRX: 53.70 (-1.69), ZQK: 1.76 (+0.03), WG: 2.82 (+0.06), SNE: 32.35 (+1.47), NVGN: 7.40 (-0.30), NBG: 1.19 (+0.12), YOD: 2.17 (+0.02), ADBE: 75.50 (+0.88), NKTR: 10.90 (+0.16), ATNM: 3.01 (-0.07), VTSS: 5.27 (-0.01), RTRX: 24.45 (+0.09), RSPP: 28.20 (-0.04), MTL: 1.29 (-0.01), EJ: 6.00 (+0.10)
Actinium Announces New Data From Ongoing Phase 1/2 Trial of Actimab-A Demonstrating Safety and Robust Clinical Efficacy in High Risk Elderly Acute Myeloid Leukemia Patients
Marketwired - Wed Mar 18, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the completion of the third cohort of the Company's ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients. Cohort 3, which included 3 additional patients, demonstrated no dose limiting toxicities in patients older than 60 and up to 87 years of age who were not eligible for currently approved therapies. Two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery (CRi). These responses were documented in the settings of high pre-treatment leukemia burdens of up to 88% in the bone marrow. In the previous cohort treated at a lower dose level of Actimab-A, one patient achieved CRi.
ATNM: 3.01 (-0.07)
Actinium to Present at the 22nd Annual Future Leaders in the Biotech Industry Conference March 20th in New York City
Marketwired - Mon Mar 16, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the Company will present at the 22nd Annual Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015 at 11:00 a.m. The conference will take place at the Millennium Broadway Hotel and Conference Center in New York City.
ATNM: 3.01 (-0.07)
Actinium Provides Business Update for 2015 and Achievements for 2014
Marketwired - Tue Mar 10, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today provided an overview of the Company's 2014 achievements and a business update for 2015. The stated achievements and highlights below demonstrate the significant progress the Company has made on key initiatives to support the advancement of the ongoing Phase 1/2 program and upcoming Phase 3 clinical development program for Actimab-A and Iomab-B, respectively. In addition, the Company continues to expand its visibility with leading bone marrow specialists; enhance its leadership team as most recently evidenced by the addition of Dr. Roland Turck, former President, Global Specialty Medicine, Bayer Healthcare as Senior Board Advisor; and is actively pursuing partnering and licensing opportunities for both products to support further clinical development across multiple indications in cancer and future commercialization.
ATNM: 3.01 (-0.07)
Metastatic Prostate Cancer Therapeutics Pipeline Review 2015 - 12 Companies & 19 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2btq2g/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actinium Pharmaceuticals, Inc. - Camurus AB - Colby Pharmaceutical Company - Eli Lilly and Company - Fountain Biopharma Inc. - Johnson & Johnson - MedImmune, LLC - MEI Pharma, Inc. - OncoMax - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. - ValiRx Plc Drug Profiles - abiraterone acetate - Actimab-P - CADD-522 - Cell Therapy to Target PSMA for Metastatic Prostate Cancer - CPC-410 - FB-704A - KGP-94 - leuprolide acetate - LU-901 - LY-2495655 - MEDI-6469 - MIP-1095 - MVI-118 - OMRCA-01 - pracinostat - Recombinant Protein for Oncology - VAC-1 - Vaccine For Oncolytic Newcastle Disease Virus - VAL-201 For more information visit http://www.researchandmarkets.com/research/2btq2g/metastatic
OXGN: 1.49 (-0.02), PGNX: 6.33 (-0.12), JNJ: 100.43 (+0.13), ATNM: 3.01 (-0.07), LLY: 72.30 (+0.09), MEIP: 2.08 (-0.16)
Actinium to Present at the 27th Annual ROTH Conference March 11th
Marketwired - Mon Mar 02, 6:01AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the Company will present at the 27th Annual ROTH Conference on Wednesday, March 11, 2015 at 10:00 a.m. The conference will take place from March 8-11, 2015 at the Ritz-Carlton Laguna Niguel, CA.
ATNM: 3.01 (-0.07)
Actinium to Partner With Aplastic Anemia & MDS International Foundation Patient and Family Forums
Marketwired - Wed Apr 22, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is partnering with the Aplastic Anemia & MDS International Foundation, a leading non-profit health organization, to present educational forums to patients and their families on bone marrow transplant, MDS, aplastic anemia and PNH. ATNM: 3.01 (-0.07)
Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 4.01 (-0.06), BIIB: 423.57 (+1.46), ARWR: 6.88 (+0.14), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), BMY: 66.60 (-0.21), CNCE: 14.83 (+0.26), CELG: 115.54 (+0.72), ATNM: 3.01 (-0.07), PFS: 18.65 (+0.06), NVIV: 13.76 (-0.19), GILD: 104.18 (-1.02), FWP: 31.77 (-0.66), GWPH: 113.04 (-0.05), IBM: 165.36 (+1.10), BAX: 70.38 (+0.33), AZN: 73.35 (+0.65), TEVA: 63.01 (-1.15)
Actinium Pharmaceuticals: An Undervalued Biotech Revolutionizing AML Treatment
Stock Doctor - Seeking Alpha - Thu Apr 16, 10:58AM CDT
Readers familiar with my biotechnology investing strategy know that I prefer small cap companies with underappreciated best-in-class drugs that address significant unmet clinical needs. I also like to pick stocks that have enough cash on hand in the...
ATNM: 3.01 (-0.07)
Actinium Doses the First Patient in the Fourth, Final Cohort of Its Actimab-A Trial
Marketwired - Wed Apr 15, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the first patient was successfully treated with Actimab-A drug candidate in the fourth and last cohort of the ongoing Phase 1/2 trial of Actimab-A. Actimab-A is being developed for newly diagnosed AML patients over the age of 60 ineligible for standard induction chemotherapy. ATNM: 3.01 (-0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 11:44AM CDT
HK: 1.60 (-0.05), TOF: 4.12 (-0.03), VTAE: 14.04 (+0.02), NYMX: 1.32 (-0.08), VLTC: 15.14 (-1.04), CGNT: 1.63 (+0.08), RESN: 3.77 (-0.06), MHR: 2.34 (-0.07), GBSN: 4.98 (+1.44), NATH: 47.21 (+0.10), INUV: 2.32 (-0.05), ATNM: 3.01 (-0.07), SYPR: 1.50 (+0.04), TRGT: 2.30 (-0.02), QURE: 26.15 (-1.44), CYTX: 0.96 (-0.09), PRXI: 4.82 (+0.27), NPTN: 5.90 (unch), CBMG: 32.14 (+2.21), SA: 6.21 (-0.29)
Actinium Pharmaceuticals Opens Enrollment for the Fourth and Final Cohort in the Company's Ongoing Phase I/II Trial in Acute Myeloid Leukemia
Marketwired - Tue Mar 24, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the fourth cohort, who, in keeping with trial protocol, will be injected with two doses 4 to 7 days apart of the Company's investigational new drug Actimab-A at a higher activity level of 2.0 micronCi/kg per dose. ATNM: 3.01 (-0.07)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 8:12AM CDT
AKRX: 53.70 (-1.69), ZQK: 1.76 (+0.03), WG: 2.82 (+0.06), SNE: 32.35 (+1.47), NVGN: 7.40 (-0.30), NBG: 1.19 (+0.12), YOD: 2.17 (+0.02), ADBE: 75.50 (+0.88), NKTR: 10.90 (+0.16), ATNM: 3.01 (-0.07), VTSS: 5.27 (-0.01), RTRX: 24.45 (+0.09), RSPP: 28.20 (-0.04), MTL: 1.29 (-0.01), EJ: 6.00 (+0.10)
Actinium Announces New Data From Ongoing Phase 1/2 Trial of Actimab-A Demonstrating Safety and Robust Clinical Efficacy in High Risk Elderly Acute Myeloid Leukemia Patients
Marketwired - Wed Mar 18, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the completion of the third cohort of the Company's ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients. Cohort 3, which included 3 additional patients, demonstrated no dose limiting toxicities in patients older than 60 and up to 87 years of age who were not eligible for currently approved therapies. Two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery (CRi). These responses were documented in the settings of high pre-treatment leukemia burdens of up to 88% in the bone marrow. In the previous cohort treated at a lower dose level of Actimab-A, one patient achieved CRi. ATNM: 3.01 (-0.07)
Actinium to Present at the 22nd Annual Future Leaders in the Biotech Industry Conference March 20th in New York City
Marketwired - Mon Mar 16, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the Company will present at the 22nd Annual Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015 at 11:00 a.m. The conference will take place at the Millennium Broadway Hotel and Conference Center in New York City. ATNM: 3.01 (-0.07)
Actinium Provides Business Update for 2015 and Achievements for 2014
Marketwired - Tue Mar 10, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today provided an overview of the Company's 2014 achievements and a business update for 2015. The stated achievements and highlights below demonstrate the significant progress the Company has made on key initiatives to support the advancement of the ongoing Phase 1/2 program and upcoming Phase 3 clinical development program for Actimab-A and Iomab-B, respectively. In addition, the Company continues to expand its visibility with leading bone marrow specialists; enhance its leadership team as most recently evidenced by the addition of Dr. Roland Turck, former President, Global Specialty Medicine, Bayer Healthcare as Senior Board Advisor; and is actively pursuing partnering and licensing opportunities for both products to support further clinical development across multiple indications in cancer and future commercialization. ATNM: 3.01 (-0.07)
Metastatic Prostate Cancer Therapeutics Pipeline Review 2015 - 12 Companies & 19 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2btq2g/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actinium Pharmaceuticals, Inc. - Camurus AB - Colby Pharmaceutical Company - Eli Lilly and Company - Fountain Biopharma Inc. - Johnson & Johnson - MedImmune, LLC - MEI Pharma, Inc. - OncoMax - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. - ValiRx Plc Drug Profiles - abiraterone acetate - Actimab-P - CADD-522 - Cell Therapy to Target PSMA for Metastatic Prostate Cancer - CPC-410 - FB-704A - KGP-94 - leuprolide acetate - LU-901 - LY-2495655 - MEDI-6469 - MIP-1095 - MVI-118 - OMRCA-01 - pracinostat - Recombinant Protein for Oncology - VAC-1 - Vaccine For Oncolytic Newcastle Disease Virus - VAL-201 For more information visit http://www.researchandmarkets.com/research/2btq2g/metastatic
OXGN: 1.49 (-0.02), PGNX: 6.33 (-0.12), JNJ: 100.43 (+0.13), ATNM: 3.01 (-0.07), LLY: 72.30 (+0.09), MEIP: 2.08 (-0.16)
Actinium to Present at the 27th Annual ROTH Conference March 11th
Marketwired - Mon Mar 02, 6:01AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the Company will present at the 27th Annual ROTH Conference on Wednesday, March 11, 2015 at 10:00 a.m. The conference will take place from March 8-11, 2015 at the Ritz-Carlton Laguna Niguel, CA. ATNM: 3.01 (-0.07)
